RAPT Therapeutics, Inc. announced plans to release topline data from its Phase 2 clinical trial of RPT904 (JYB1904) in patients with chronic spontaneous urticaria (CSU) on Monday, October 20, 2025. The South San Francisco-based clinical-stage immunology company will present the results through a premarket press release and webcast at 8:30 a.m. ET.
Partnership-Driven Development
The Phase 2 trial was conducted by RAPT's partner, Shanghai Jeyou Pharmaceutical Co., Ltd. (Jeyou), formerly known as Shanghai Jemincare Pharmaceutical Co., Ltd. This collaboration represents RAPT's strategic approach to advancing its pipeline through international partnerships while maintaining focus on novel immunology-based therapeutics.
Novel Therapeutic Approach
RPT904 is designed to modulate critical immune responses underlying inflammatory and immunological diseases. The drug candidate represents RAPT's deep expertise in immunology and its commitment to developing therapies that address the root causes of inflammatory conditions rather than merely managing symptoms.
Clinical Trial Significance
Chronic spontaneous urticaria affects patients with recurring hives and swelling without an identifiable trigger. The condition can significantly impact quality of life, making effective treatments a priority for both patients and healthcare providers. The upcoming data release will provide insights into RPT904's potential efficacy and safety profile in this patient population.
Company Focus and Pipeline
RAPT Therapeutics positions itself as a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapies for patients with inflammatory and immunological diseases. The company leverages its proprietary expertise in immunology to develop treatments that target the underlying mechanisms of these conditions.
Data Presentation Details
The company will host a webcast conference call accompanied by a slide presentation, allowing investors and stakeholders to participate in a live Q&A session. Pre-registration is required for phone participation, with the live webcast and audio archive accessible through the RAPT Therapeutics investor website.
The October 20 data release represents a critical milestone for RAPT's development program and could provide important insights into the therapeutic potential of RPT904 for chronic spontaneous urticaria patients.
